NEW YORK, July 18, 2013 /PRNewswire/ -- OTC Markets
Group Inc. (OTCQX: OTCM), operator of Open, Transparent and
Connected financial marketplaces, today announced that Cynapsus
Therapeutics Inc. (OTCQX: CYNAF; TSX.V: CTH), a Canada-based specialty pharmaceutical company,
has been approved to trade on OTCQX®, the best marketplace with
qualified companies.
(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO
)
Cynapsus Therapeutics began trading today on OTCQX
International, a segment of the OTCQX marketplace reserved for
high-quality non-U.S. companies that are listed on a qualified
international exchange, undergo management reviews and provide
their home country disclosure to U.S. investors. U.S.
investors can find current financial disclosures and Real-Time
Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased to welcome Cynapsus Therapeutics to OTCQX," said
R. Cromwell Coulson, President and
CEO of OTC Markets Group. "OTCQX provides qualifying
companies like Cynapsus the ability to distinguish themselves in
the U.S. market and increase their visibility with traders,
investors, analysts and the media through high-quality disclosure,
transparent trading and ease of access to company
information. We look forward to supporting the management
team at Cynapsus as they continue to grow the company and provide a
robust public market for their shares."
"Qualifying for OTCQX is an important milestone for Cynapsus and
demonstrates our commitment to providing our U.S. investors
convenient access to the same timely news and information enjoyed
by investors in our home market," said Anthony Giovinazzo, President and CEO of
Cynapsus Therapeutics.
Troutman Sanders LLP will serve as Cynapsus Therapeutics'
Principal American Liaison ("PAL") on OTCQX, responsible for
providing professional guidance on OTCQX requirements and U.S.
securities laws.
Cynapsus is a specialty pharmaceutical company developing the
only non-injectable (i.e., sublingual) delivery of the only
approved drug (apomorphine) to be used as a rescue therapy for
"off" motor symptoms of Parkinson's disease.
Cynapsus Therapeutics trades in the U.S. on OTCQX under the
symbol "CYNAF."
About OTC Markets Group Inc.
OTC Markets Group Inc.
(OTCQX: OTCM) operates Open, Transparent and Connected financial
marketplaces for 10,000 U.S. and global securities. Through our OTC
Link® ATS, we directly link a diverse network of broker-dealers
that provide liquidity and execution services for a wide spectrum
of securities. We organize these securities into marketplaces to
better inform investors of opportunities and risks – OTCQX®, The
Best Marketplace with Qualified Companies; OTCQB®, The Venture
Stage Marketplace with U.S. Reporting Companies; and OTC Pink®, The
Open Marketplace with Variable Reporting Companies. Our data-driven
platform enables investors to easily trade through the broker of
their choice at the best possible price and empowers a broad range
of companies to improve the quality and availability of information
for their investors. To learn more about how we create better
informed and more efficient financial marketplaces, visit
www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and
SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
SOURCE OTC Markets Group Inc.